872 - Ketamine and Esketamine

Ketamine is in the news again. In this episode: a conversation about the differences between ketamine and esketamine—an FDA-approved medicine for treatment-resistant depression—why we’re hearing so much about ketamine right now, and the importance of administering esketamine in a clinical setting as part of a broader comprehensive mental health strategy.

Dr. Paul Kim is a psychiatrist and director of the Johns Hopkins Treatment Resistant Esketamine Antidepressant Targeted (TREAT) Depression Clinic.

Dr. Paul Nestadt is a psychiatrist and co-director of the Johns Hopkins Treatment Resistant Esketamine Antidepressant Targeted (TREAT) Depression Clinic.

Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health.

• What to Know About Ketamine—Johns Hopkins Bloomberg School of Public Health

• Esketamine for Treatment-Resistant Depression—Hopkins Medicine

• What Ketamine Does to the Human Brain—The Atlantic

Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel.

Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.

• @‌PublicHealthPod on Bluesky

• @‌JohnsHopkinsSPH on Instagram

• @‌JohnsHopkinsSPH on Facebook

• @‌PublicHealthOnCall on YouTube

• Here's our RSS feed